MediFind

Find a Doctor

Helen J. Gogas

National And Kapodistrian University Of Athens School Of Medicine
Female

Bio


Helen Gogas is in Athens, Greece. They have been an author on 213 peer reviewed articles in the past 15 years. Dr. Gogas's top three areas of expertise are Melanoma, Breast Cancer, and Triple-Negative Breast Cancer.

Contact

Athens, ESYE31, GR

Latest Research


Latest Advance
Study
  • Condition: BRAF V600-Mutant Melanoma
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Treatment Used: Encorafenib plus Binimetinib vs. Vemurafenib or Encorafenib
  • Number of Patients: 577
  • Published —
This study reported updated analysis of the COLUMBUS (COmbined LGX818 Used with MEK162 in BRAF mutant Unresectable Skin cancer) trial with long-term follow-up.
Latest Advance
Study
  • Condition: Advanced Melanoma in Patients whose Cancer Progressed after Treatment with Ipilimumab
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Treatment Used: Nivolumab
  • Number of Patients: 1008
  • Published —
The purpose of this study was to evaluate the effectiveness of nivolumab in patients whose cancer progressed after treatment with ipilimumab
Latest Advance
Study
  • Condition: Metastatic breast cancer
  • Journal: Journal of chemotherapy (Florence, Italy)
  • Treatment Used: Capecitabine and brivudine
  • Number of Patients: 1
  • Published —
The study discusses one patient's experience with using capecitabine and brivudine to treat metastatic breast cancer.
Latest Advance
Study
  • Condition: Rare melanoma subtypes who have progressed on or after ipilimumab treatment
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Treatment Used: Nivolumab
  • Number of Patients: 1008
  • Published —
The study researched the effects of Nivolumab for patients with rare melanoma subtypes who have progressed on or after ipilimumab treatment.
Latest Advance
Study
  • Condition: BRAFV600-Mutant Metastatic Melanoma
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Treatment Used: Encorafenib plus Binimetinib
  • Number of Patients: 570
  • Published —
The purpose of this study was to fully describe the adverse effects of encorafenib plus binimetinib treatment in patients with BRAFV600-mutant metastatic melanoma.
Latest Advance
Study
  • Condition: Unresectable or Metastatic Melanoma
  • Journal: The New England journal of medicine
  • Treatment Used: Dabrafenib Plus Trametinib
  • Number of Patients: 563
  • Published —
This study determined 5-year survival rates of patients with unresectable or metastatic melanoma (advanced skin cancer) treated with combination of chemotherapy drugs dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitors).
Latest Advance
Study
  • Condition: BRAF-Mutant Melanoma
  • Journal: Cancer immunology, immunotherapy : CII
  • Treatment Used: Anti-PD-1 Monotherapy vs. BRAF/MAPK/ERK Kinase (MEK) Combined Inhibition for First-Line Therapy
  • Number of Patients: 301
  • Published —
This study analyzed anti-PD-1 monotherapy versus BRAF/MAPK/ERK kinase (MEK) combined inhibition used as first-line agents for the treatment of BRAF-mutant melanoma.
Latest Advance
Study
  • Condition: BRAF V600-Mutant Metastatic Melanoma
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Treatment Used: Vemurafenib
  • Number of Patients: 3224
  • Published —
This study tested the safety and efficacy of using vemurafenib to treat patients with BRAF V600-mutant metastatic melanoma.
Latest Advance
Study
  • Condition: BRAF Wild-Type Advanced Melanoma
  • Journal: JAMA oncology
  • Treatment Used: Nivolumab Versus Dacarbazine
  • Number of Patients: 418
  • Published —
In this study, researchers compared the effectiveness of nivolumab versus dacarbazine for the treatment of BRAF wild-type advanced melanoma.
Latest Advance
Study
  • Condition: BRAFV600-Mutant Melanoma
  • Journal: The Lancet. Oncology
  • Treatment Used: Encorafenib plus Binimetinib vs. Vemurafenib vs. Encorafenib
  • Number of Patients: 1345
  • Published —
The purpose of the study was to compare the effectiveness of encorafenib plus binimetinib vs. vemurafenib vs. encorafenib in the treatment of a type of skin cancer (BRAFV600 mutant melanoma).
Latest Advance
Study
  • Condition: BRAF-mutant melanoma
  • Journal: The Lancet. Oncology
  • Treatment Used: Encorafenib plus binemetibinib versus vemurafenib or encorafenib
  • Number of Patients: 577
  • Published —
This study investigated encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma.

Clinical Trials


This doctor has not participated in any recent clinical trials.

All Publications
View All


Contact

Athens, ESYE31, GR

Insurance

Contact them to find out if they accept your insurance plan.